471 related articles for article (PubMed ID: 19954478)
21. The RAGE axis and endothelial dysfunction: maladaptive roles in the diabetic vasculature and beyond.
Ramasamy R; Yan SF; Schmidt AM
Trends Cardiovasc Med; 2005 Oct; 15(7):237-43. PubMed ID: 16226677
[TBL] [Abstract][Full Text] [Related]
22. Role of advanced glycation end products and their receptors in development of diabetic neuropathy.
Wada R; Yagihashi S
Ann N Y Acad Sci; 2005 Jun; 1043():598-604. PubMed ID: 16037282
[TBL] [Abstract][Full Text] [Related]
23. AGE-RAGE and AGE Cross-link interaction: important players in the pathogenesis of diabetic kidney disease.
Jensen LJ; Østergaard J; Flyvbjerg A
Horm Metab Res; 2005 Apr; 37 Suppl 1():26-34. PubMed ID: 15918107
[TBL] [Abstract][Full Text] [Related]
24. RAGE-mediated neutrophil dysfunction is evoked by advanced glycation end products (AGEs).
Collison KS; Parhar RS; Saleh SS; Meyer BF; Kwaasi AA; Hammami MM; Schmidt AM; Stern DM; Al-Mohanna FA
J Leukoc Biol; 2002 Mar; 71(3):433-44. PubMed ID: 11867681
[TBL] [Abstract][Full Text] [Related]
25. [Diabetic macrovascular complications].
Yamagishi S
Nihon Rinsho; 2015 Mar; 73(3):479-83. PubMed ID: 25812377
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of protein kinase C might be harmful to diabetic retinopathy.
Yamagishi S; Takeuchi M
Med Hypotheses; 2004; 63(1):135-7. PubMed ID: 15193366
[TBL] [Abstract][Full Text] [Related]
27. Advanced glycation endproducts and their receptor RAGE in Alzheimer's disease.
Srikanth V; Maczurek A; Phan T; Steele M; Westcott B; Juskiw D; Münch G
Neurobiol Aging; 2011 May; 32(5):763-77. PubMed ID: 19464758
[TBL] [Abstract][Full Text] [Related]
28. Oral administration of AST-120 (Kremezin) is a promising therapeutic strategy for advanced glycation end product (AGE)-related disorders.
Yamagishi S; Nakamura K; Matsui T; Inoue H; Takeuchi M
Med Hypotheses; 2007; 69(3):666-8. PubMed ID: 17331665
[TBL] [Abstract][Full Text] [Related]
29. Possible participation of advanced glycation end products in the pathogenesis of colorectal cancer in diabetic patients.
Yamagishi S; Nakamura K; Inoue H; Kikuchi S; Takeuchi M
Med Hypotheses; 2005; 64(6):1208-10. PubMed ID: 15823719
[TBL] [Abstract][Full Text] [Related]
30. Effect of protocatechualdehyde on receptor for advanced glycation end products and TGF-beta1 expression in human lens epithelial cells cultured under diabetic conditions and on lens opacity in streptozotocin-diabetic rats.
Kim YS; Kim NH; Lee SW; Lee YM; Jang DS; Kim JS
Eur J Pharmacol; 2007 Aug; 569(3):171-9. PubMed ID: 17597607
[TBL] [Abstract][Full Text] [Related]
31. Advanced Glycation End Products: A Molecular Target for Vascular Complications in Diabetes.
Yamagishi S; Nakamura N; Suematsu M; Kaseda K; Matsui T
Mol Med; 2015 Oct; 21 Suppl 1(Suppl 1):S32-40. PubMed ID: 26605646
[TBL] [Abstract][Full Text] [Related]
32. Possible participation of advanced glycation end products in the pathogenesis of osteoporosis in diabetic patients.
Yamagishi S; Nakamura K; Inoue H
Med Hypotheses; 2005; 65(6):1013-5. PubMed ID: 16146671
[TBL] [Abstract][Full Text] [Related]
33. Deposition of advanced glycation end products (AGE) and expression of the receptor for AGE in cardiovascular tissue of the diabetic rat.
Sun M; Yokoyama M; Ishiwata T; Asano G
Int J Exp Pathol; 1998 Aug; 79(4):207-22. PubMed ID: 9797717
[TBL] [Abstract][Full Text] [Related]
34. Nifedipine inhibits gene expression of receptor for advanced glycation end products (RAGE) in endothelial cells by suppressing reactive oxygen species generation.
Yamagishi S; Takeuchi M
Drugs Exp Clin Res; 2004; 30(4):169-75. PubMed ID: 15553663
[TBL] [Abstract][Full Text] [Related]
35. Receptor for advanced glycation end products and its ligands: a journey from the complications of diabetes to its pathogenesis.
Kim W; Hudson BI; Moser B; Guo J; Rong LL; Lu Y; Qu W; Lalla E; Lerner S; Chen Y; Yan SS; D'Agati V; Naka Y; Ramasamy R; Herold K; Yan SF; Schmidt AM
Ann N Y Acad Sci; 2005 Jun; 1043():553-61. PubMed ID: 16037278
[TBL] [Abstract][Full Text] [Related]
36. Advanced glycation end-products in diabetes mellitus, with particular reference to angiopathy.
Chiarelli F; Mansour M; Verrotti A
Diabetes Nutr Metab; 2000 Aug; 13(4):192-9. PubMed ID: 10961486
[No Abstract] [Full Text] [Related]
37. Advanced glycation end-products (AGEs): involvement in aging and in neurodegenerative diseases.
Grillo MA; Colombatto S
Amino Acids; 2008 Jun; 35(1):29-36. PubMed ID: 18008028
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of tissue accumulation levels of advanced glycation end products by skin autofluorescence: A novel marker of vascular complications in high-risk patients for cardiovascular disease.
Yamagishi S; Fukami K; Matsui T
Int J Cardiol; 2015 Apr; 185():263-8. PubMed ID: 25814214
[TBL] [Abstract][Full Text] [Related]
39. A study on serum advanced glycation end products and its association with oxidative stress and paraoxonase activity in type 2 diabetic patients with vascular complications.
Bansal S; Chawla D; Siddarth M; Banerjee BD; Madhu SV; Tripathi AK
Clin Biochem; 2013 Jan; 46(1-2):109-14. PubMed ID: 23103709
[TBL] [Abstract][Full Text] [Related]
40. AGEs, rather than hyperglycemia, are responsible for microvascular complications in diabetes: a "glycoxidation-centric" point of view.
Chilelli NC; Burlina S; Lapolla A
Nutr Metab Cardiovasc Dis; 2013 Oct; 23(10):913-9. PubMed ID: 23786818
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
